KAI Pharmaceuticals

Biotechnology, Medical, Therapeutics
Founded in 2002-01-01
South San Francisco, California, United States
http://www.kaipharmaceuticals.com
For Profit

About KAI Pharmaceuticals

KAI Pharmaceuticals is a drug discovery and development company with multiple, novel clinical-stage programs in the areas of cardiovascular disease, kidney disease and pain. KAI lead product candidate, KAI-9803, is currently in a Phase 2b study (PROTECTION AMI) designed to assess the effect of KAI-9803 on reducing myocardial injury in heart attack patients. KAI second core program, KAI-4169 for the treatment of secondary hyperparathyroidism (SHPT) in kidney disease patients, is expected to enter human clinical trials in 2010. KAI also has an ongoing pain program, KAI-1678, which is currently in Phase 2a testing.

Company Metrics

  • Employees: 10001+
  • Monthly Visits: None
  • Tech Stack: 5 active products

Financial Information

  • Estimated Revenue:
  • Total Funding: 52000000 USD
  • Last Funding: 35000000 USD (Series B)
  • Funding Status: M&A

Technology Stack

KAI Pharmaceuticals actively uses 5 products in their tech stack.

Market Presence

Industries: Biotechnology, Medical, Therapeutics

Headquarters: South San Francisco, California, United States